Stock Scorecard
Stock Summary for Vivos Therapeutics Inc (VVOS) - $3.25 as of 10/7/2025 12:23:18 PM EST
Total Score
9 out of 30
Safety Score
22 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VVOS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VVOS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VVOS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for VVOS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for VVOS (22 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for VVOS
Financial Details for VVOS
Company Overview |
|
|---|---|
| Ticker | VVOS |
| Company Name | Vivos Therapeutics Inc |
| Country | USA |
| Description | Vivos Therapeutics, Inc. (VVOS) is an innovative medical technology company focused on transforming the treatment landscape for sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA). Based in Highlands Ranch, Colorado, Vivos is committed to advancing non-invasive therapeutic solutions that address the root causes of these conditions, thereby enhancing patient outcomes. The company leverages its proprietary technology to create effective, user-friendly treatment options that aim to improve the quality of life for individuals suffering from insomnia and related disorders in a rapidly growing healthcare market. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/12/2025 |
Stock Price History |
|
| Last Day Price | 3.25 |
| Price 4 Years Ago | 56.25 |
| Last Day Price Updated | 10/7/2025 12:23:18 PM EST |
| Last Day Volume | 553,521 |
| Average Daily Volume | 367,313 |
| 52-Week High | 7.95 |
| 52-Week Low | 1.98 |
| Last Price to 52 Week Low | 64.14% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 44.24 |
| Sector PE | 41.70 |
| 5-Year Average PE | -14.76 |
| Free Cash Flow Ratio | 5.51 |
| Industry Free Cash Flow Ratio | 37.96 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 1.05 |
| Total Cash Per Share | 0.59 |
| Book Value Per Share Most Recent Quarter | 0.63 |
| Price to Book Ratio | 5.24 |
| Industry Price to Book Ratio | 3.99 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 1.70 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.50 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 7,504,800 |
| Market Capitalization | 24,390,600 |
| Institutional Ownership | 10.57% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 18.02% |
| Reported EPS 12 Trailing Months | -1.16 |
| Reported EPS Past Year | -1.03 |
| Reported EPS Prior Year | -2.91 |
| Net Income Twelve Trailing Months | -14,320,000 |
| Net Income Past Year | -11,136,000 |
| Net Income Prior Year | -13,583,000 |
| Quarterly Revenue Growth YOY | -5.80% |
| 5-Year Revenue Growth | 5.70% |
| Operating Margin Twelve Trailing Months | -127.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 4,402,000 |
| Total Cash Past Year | 6,260,000 |
| Total Cash Prior Year | 1,643,000 |
| Net Cash Position Most Recent Quarter | -3,358,000 |
| Net Cash Position Past Year | 4,995,000 |
| Long Term Debt Past Year | 1,265,000 |
| Long Term Debt Prior Year | 1,265,000 |
| Total Debt Most Recent Quarter | 7,760,000 |
| Equity to Debt Ratio Past Year | 0.86 |
| Equity to Debt Ratio Most Recent Quarter | 0.37 |
| Total Stockholder Equity Past Year | 7,954,000 |
| Total Stockholder Equity Prior Year | 411,000 |
| Total Stockholder Equity Most Recent Quarter | 4,583,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -15,686,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.09 |
| Free Cash Flow Past Year | -13,259,000 |
| Free Cash Flow Prior Year | -12,749,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.28 |
| MACD Signal | -0.29 |
| 20-Day Bollinger Lower Band | 1.53 |
| 20-Day Bollinger Middle Band | 3.90 |
| 20-Day Bollinger Upper Band | 6.27 |
| Beta | 6.87 |
| RSI | 38.13 |
| 50-Day SMA | 6.75 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 15.77 |
System |
|
| Modified | 10/7/2025 12:24:04 PM EST |